期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
康艾注射液联合恩替卡韦治疗中晚期肝癌伴慢性乙型肝炎的Meta分析 被引量:10
1
作者 马骁 文建霞 +2 位作者 李浩田 魏士长 赵艳玲 《中成药》 CAS CSCD 北大核心 2018年第10期2157-2164,共8页
目的对康艾注射液联合恩替卡韦治疗中晚期肝癌伴慢性乙型肝炎进行Meta分析。方法计算机检索CNKI、万方、维普、CBM、Pubmed、Embase、Cochrane Library数据库,纳入关于康艾注射液联合恩替卡韦治疗中晚期肝癌伴慢性乙型肝炎的随机对照试... 目的对康艾注射液联合恩替卡韦治疗中晚期肝癌伴慢性乙型肝炎进行Meta分析。方法计算机检索CNKI、万方、维普、CBM、Pubmed、Embase、Cochrane Library数据库,纳入关于康艾注射液联合恩替卡韦治疗中晚期肝癌伴慢性乙型肝炎的随机对照试验文献,评价其方法学质量,通过Rev Man 5. 3软件对结局指标进行Meta分析。结果共纳入8篇文献,751例患者,所有文献均具有一定偏倚。与对照组(单用恩替卡韦或康艾注射液)比较,试验组(康艾注射液联合恩替卡韦)可显著提高生存质量有效率(P <0. 05),增加保肝作用(显著降低ALT、AST、TBIL,显著升高ALB,P <0. 05)、凝血功能(显著降低PT、TT、FIB,P <0. 05;对APTT无显著影响,P> 0. 05)、抗病毒活性(显著降低HBV-DNA,P <0. 05)、抑制肿瘤细胞能力(显著降低AFP,P <0. 05); 2组不良反应发生率无显著性差异(P> 0. 05)。结论康艾注射液联合恩替卡韦治疗中晚期肝癌伴慢性乙型肝炎时,生活质量有效率、安全性更高,疗效更理想。 展开更多
关键词 康艾注射液 恩替卡韦 中晚期肝癌 慢性乙型肝炎 META分析
下载PDF
康艾注射液联合TACE治疗原发性肝癌的Meta分析 被引量:14
2
作者 马骁 何璇 +3 位作者 李浩田 魏士长 邹亚峰 赵艳玲 《中成药》 CAS CSCD 北大核心 2019年第7期1564-1572,共9页
目的对康艾注射液联合肝动脉插管栓塞化疗术(TACE)治疗原发性肝癌进行Meta分析。方法检索CNKI、万方、维普、CBM、Pubmed、Embase、Cochrane Library数据库,时间从建库起至2018年12月,筛选康艾注射液联合TACE治疗原发性肝癌的随机对照... 目的对康艾注射液联合肝动脉插管栓塞化疗术(TACE)治疗原发性肝癌进行Meta分析。方法检索CNKI、万方、维普、CBM、Pubmed、Embase、Cochrane Library数据库,时间从建库起至2018年12月,筛选康艾注射液联合TACE治疗原发性肝癌的随机对照试验文献,评定其方法学质量,并对结局指标进行合成分析。结果共纳入12项研究,747例患者,均具有一定偏倚风险。与对照组(TACE)比较,观察组(康艾注射液+TACE)可显著增加有效率,提升KPS评分(P<0.05),显著提高T细胞亚群CD3、CD4、CD8及NK细胞活性(P<0.05),同时康艾注射液在50~60 mL、30~60 d条件下联合TACE的临床疗效更显著(P<0.05)。另外,观察组一般不良反应发生率及血液学毒性、肝功能损伤发生率显著低于对照组(P<0.05),但2组肾功能损伤无显著差异(P>0.05)。结论康艾注射液联合TACE治疗原发性肝癌有效率更高,患者生活质量更好,不良反应发生率更低。 展开更多
关键词 康艾注射液 肝动脉插管栓塞化疗术(TACE) 原发性肝癌 META分析
下载PDF
San-Cao Granule (三草颗粒) Ameliorates Hepatic Fibrosis through High Mobility Group Box-1 Protein/Smad Signaling Pathway 被引量:2
3
作者 wei shi-zhang LUO Sheng-qiang +15 位作者 WANG Jian WANG Jia-bo LI Rui-sheng ZHANG Xiao-mei GUO Yan-lei CHEN Chang MA Xiao CHEN Zhe LIU Hong-hong YANG Zhi-rui LI Jian-yu WANG Rui-lin ZHANG Ya-ming YANG Hui-yin XIAO Xiao-he ZHAO Yan-ling 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2018年第7期502-511,共10页
Objective: To investigate the possible mechanism of San-Cao Granule(SCG, 三草颗粒) mediating antiliver fibrosis. Methods: A total of 60 male Sprague-Dawley rats were randomly divided into the normal control group,... Objective: To investigate the possible mechanism of San-Cao Granule(SCG, 三草颗粒) mediating antiliver fibrosis. Methods: A total of 60 male Sprague-Dawley rats were randomly divided into the normal control group, porcine serum-treated group, ursodesoxycholic acid(UDCA, 60 mg/kg), SCG(3.6 g/kg) group, SCG(1.8 g/kg) group and SCG(0.9 g/kg) group, with 10 rats in each group. Liver fibrosis was induced with porcine serum by intraperitoneal injection for 8 weeks, except for the normal control group. Then, the rats in the three SCG-treated groups and UDCA group were administered SCG and UDCA respectively for 4 weeks. The serum levels of alanine transaminase(ALT), aspartate transaminase(AST), albumin(ALB), total bilirubin(TBIL), hyaluronic acid(HA), laminin(LN), and type Ⅳcollagen(ⅣC) were examined using commercial kits and hepatic histopathology was examined with hematoxylin and eosin and Masson staining. Moreover, the protein expression levels of high mobility group box-1 protein(HMGB1), transforming growth factor β1(TGF-β1), phosphorylated mothers against decapentaplegic homolog 3(p-Smad3), Smad7, toll-like receptor 4(TLR4), myeloid differentiation factor 88(My D88), nuclear factor-kappa B(NF-κB) and α-smooth muscle actin(α-SMA) were determined by western blot, immunohistochemistry and real time quantitativereverse transcription polymerase. Results: Both SCG(3.6 and 1.8 g/kg) and UDCA significantly ameliorated the liver fibrosis induced by porcine serum as indicated by retarding the serum levels increasing of ALT, AST, TBIL, HA, LN and ⅣC and preventing the serum level reducing of ALB compared with the model group(all P〈0.01). Meanwhile, the collagen deposition was attenuated by SCG and UDCA treatment. Furthermore, SCG markedly reduced the expressions of HMGB1, TGF-β1, p-Smad3, TLR4, My D88, NF-κB and α-SMA, and enhanced the expression of the Smad7 compared with the model group(all P〈0.01). Conclusion: SCG ameliorates hepatic fibrosis possibly through inhibiting HMGB1, TLR4/NF-κB and TGF-β1/Smad signaling pathway. 展开更多
关键词 San-Cao Granule liver fibrosis high mobility group box-1 protein toll-like receptor 4/nuclear factor-kappa B transforming growth factor β1/mothers against decapentaplegic homolog
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部